RxDoctor Payments Data

David Fitch, MD

Gastroenterology · Cincinnati, OHNPI 1699110684

Payments from drug & device makers

$4,653in general payments, 2019–2025

Across 270 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$500
  • Regeneron Healthcare Solutions, Inc.$332
  • Johnson & Johnson$325
  • E.r. Squibb & Sons, L.L.C.$115
  • plus $858 from 20 others

What the payments were for

  • Consulting fees$1,15625%
  • Food & beverage$3,29971%
  • Education$1984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,653 in reported general payments places this provider in the 60th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$86,722
Medicare patients
226
Services billed
1,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$356,178
XifaxanRifaximin20$60,565
LinzessLinaclotide51$35,837
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates97$6,060
Omeprazole248$1,889
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C13$1,767
Ursodiol22$1,741
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag13$1,627
Pantoprazole Sodium115$1,202
Budesonide DrBudesonide12$952
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl51$689
Entecavir11$572
Ondansetron OdtOndansetron32$503
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl24$419
Amitriptyline Hcl15$187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$325$356,17813 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu$90$62,33233 claims
AbbVieLinzess$1,351$35,83751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →